{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:10:08Z","timestamp":1785413408407,"version":"3.56.0"},"reference-count":56,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Acute myeloid leukemia (AML) with myelodysplasia-related gene mutations (AML-MR), often referred to as secondary AML (s-AML) or AML-MRC, is an aggressive form of leukemia that typically arises from an antecedent myelodysplastic syndrome (MDS) but may also originate de novo. It is characterized by mutations in key genes associated with MDS that include some epigenetic regulators (ASXL1 and EZH2), splicing factors (SF3B1, SRSF2, U2AF1, and ZRSR2), and transcription factors (BCOR, RUNX1, and STAG2). The main objective of this review paper consists of analyzing recent studies that have improved the criteria for the characterization, definition, and classification of AML-MR. Methods: An extensive search of the most recent literature on the topic was performed, selecting and critically analyzing the most relevant studies. Results. The studies carried out in the last few years have provided an extensive molecular characterization of AML-MR, supporting sounder criteria for identification and a better definition with respect to other AML subtypes, particularly with respect to TP53-mutant AML. Conclusions: A unifying classification of AML-MR is now possible, allowing its identification as a unique, well-defined, and separate entity.<\/jats:p>","DOI":"10.3390\/jcm15155958","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:38:54Z","timestamp":1785411534000},"page":"5958","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute Myeloid Leukemia with Myelodysplasia-Related Gene Mutations"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-8942","authenticated-orcid":false,"given":"Ugo","family":"Testa","sequence":"first","affiliation":[{"name":"Department of Oncology, Istituto Superiore di Sanit\u00e0, Viale Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in acute myeloid leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision of the world health organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of hematolymphoid tumors: Myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41408-025-01258-0","article-title":"Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: A report from the Beat AML okclinical trial","volume":"15","author":"Hoff","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-022-00774-7","article-title":"Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML","volume":"13","author":"Tsai","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1038\/s41375-025-02644-0","article-title":"Multi-dimensional analysis of AML cross-continent reveals age-associated trends in mutational landscape and treatment outcomes (AML Cooperation Group and Alliance for Clinical Trials in Oncology)","volume":"39","author":"Cusan","year":"2025","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","article-title":"Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients","volume":"37","author":"Jahn","year":"2023","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","article-title":"Outcome prediction by the 2022 European Leukemia Net genetic-risk classification for adults with acute myeloid leukemia: An Alliance study","volume":"37","author":"Mrozek","year":"2023","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European Leukemia Net genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/bloodadvances.2023011869","article-title":"A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: A comparison of ICC and WHO-HAEM criteria","volume":"8","author":"Zhou","year":"2024","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/s41375-025-02622-6","article-title":"Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia","volume":"39","author":"Mecklenbrauck","year":"2025","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41375-025-02781-6","article-title":"Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients","volume":"40","author":"Bill","year":"2026","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood.2023020649","article-title":"Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia","volume":"142","author":"Senapati","year":"2023","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ccell.2022.12.002","article-title":"Modulation of RNA splicing enhances responses in BCL2 inhibition in leukemia","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1007\/s00277-025-06399-7","article-title":"Selective efficacy of venetoclax in unfit patients with acute myeloid leukemia with myelodysplasia-related gene mutations under low-intensity therapy","volume":"104","author":"Lin","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/bloodadvances.2025018408","article-title":"MDS\/AML and AML with myelodysplasia-related gene mutations: Clinical and molecular similarities","volume":"10","author":"Bortjes","year":"2026","journal-title":"Blood Adv."},{"key":"ref_21","first-page":"13451377","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"14","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e70174","DOI":"10.1002\/hon.70174","article-title":"Comparative analysis of ICC and WHO classifications reveal molecular and clinical convergence between AML-MR and MDS\/AML","volume":"44","author":"Wei","year":"2026","journal-title":"Hematol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Attardi, E., Cipriani, M., Guarnera, L., Savi, A., Fabiani, E., Mallegni, F., Moretti, F., Silvestrini, G., Awada, H., and Durmaz, A. (2026). Validation of ICC hierarchical classification in secondary AML. Blood Adv., in press.","DOI":"10.1182\/bloodadvances.2025018188"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1182\/bloodadvances.2025018770","article-title":"A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS natural history study","volume":"10","author":"Gillis","year":"2026","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.3324\/haematol.2015.127985","article-title":"Karyotype evolution and acquisition of FLT3 or RAS pathways alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia","volume":"100","author":"Meggendorfer","year":"2015","journal-title":"Haematologica"},{"key":"ref_26","first-page":"2157","article-title":"Patterns of lower risk myelody splastic progression: Factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia","volume":"1019","author":"Jain","year":"2024","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2643-3230.BCD-21-0128","article-title":"Distinct patterns of clonal evolution drive myelodysplastic syndrome progression to secondary acute myeloid leukemia","volume":"3","author":"Guess","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_28","first-page":"3430","article-title":"Convergent clonal evolution is a hallmark of myelodysplastic syndrome progression","volume":"3","author":"Menssen","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_29","first-page":"330","article-title":"The seeds of progression from myelodysplasia syndrome to acute myeloid leukemia are sown early in the of disease","volume":"19","author":"Hasserjian","year":"2002","journal-title":"Hematologist"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1182\/bloodadvances.2023009675","article-title":"Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia","volume":"5","author":"McCarter","year":"2023","journal-title":"Blood Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ajh.27561","article-title":"Outcomes of patients with treated secondary acute myeloid leukemia: A high risk subtype that warrants an independent prognostic designation","volume":"100","author":"Senapati","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2025-219","article-title":"Unifying the classification of acute myeloid leukemia, myelodysplasia-related: A multi-institutional experience","volume":"146","author":"Liu","year":"2025","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41375-026-02874-w","article-title":"Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia","volume":"40","author":"Mecklenbrauck","year":"2026","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/leu.2013.165","article-title":"Dynamic acquisition of FLT3 or RAS alterations drive a subset of patents with lower risk MDS to secondary AML leukemia","volume":"27","author":"Takahashi","year":"2013","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.leukres.2015.10.005","article-title":"Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/s41375-023-02016-6","article-title":"Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia\u2014Implications for the European Leukemia Net risk classification","volume":"37","author":"Eckardt","year":"2023","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1 mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/bloodadvances.2023011173","article-title":"Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML","volume":"8","author":"Chan","year":"2024","journal-title":"Blood Adv."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1182\/blood-2025-6999","article-title":"impact of MDS-associated mutations and age on outcomes in NPM1-mutated AML","volume":"146","author":"Liu","year":"2025","journal-title":"Blood"},{"key":"ref_40","first-page":"e70060","article-title":"Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML","volume":"9","author":"Cocciardi","year":"2025","journal-title":"Hemapshere"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Chang, Y.S., Lee, Y.W., and Liu, C.Y. (2026). Prognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: A systematic review and meta-analysis. Haematologica, in press.","DOI":"10.3324\/haematol.2026.300922"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Desai, N., and Mattsson, J. (2026). Do myelodysplasia-related gene mutations after transplant decisions in NPM1-mutated acute myeloid leukemia? Comment on \u201cPrognostic implications of myelodysplasia-related gene mutations in NPM1-mutated acute myeloid leukemia: A systematic review and meta-analysis\u201d. Haematologica, in press.","DOI":"10.3324\/haematol.2026.300857"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2636337","DOI":"10.1080\/07853890.2026.2636337","article-title":"Prognostic impact of myelodysplasia-related gene mutations in ELN-2022 favorable-risk acute myeloid leukemia subtypes","volume":"58","author":"Zhou","year":"2026","journal-title":"Ann. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2024-200413","article-title":"AML-MR mutations drive the benefit of CPX-351 over 7+3 in the pivotal phase 3 AML trial","volume":"144","author":"Shimony","year":"2024","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/bloodadvances.2025017089","article-title":"Impact of fitness categorization according to SIE\/SIES\/GITMO criteria in therapy-related and AML-MRC receiving CPX-351","volume":"10","author":"Palmieri","year":"2026","journal-title":"Blood Adv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/bloodadvances.2023010276","article-title":"A randomized of CPX-351 and FLG-Ida in adverse karyotype AML and high-risk MDS: The UK NCRI AML19 trial","volume":"7","author":"Othman","year":"2023","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41375-024-02230-w","article-title":"Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41375-024-02175-0","article-title":"Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41408-026-01495-x","article-title":"CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients","volume":"16","author":"Fathima","year":"2026","journal-title":"Blood Cancer J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/bjh.70274","article-title":"Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium","volume":"208","author":"Peters","year":"2026","journal-title":"Br. J. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41375-025-02625-3","article-title":"Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax\/azacitidine for AML","volume":"39","author":"Ikoma","year":"2025","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e70214","DOI":"10.1002\/hem3.70214","article-title":"A phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia","volume":"9","author":"Jen","year":"2025","journal-title":"Hemasphere"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1182\/blood-2025-3423","article-title":"Phase 2 study of SLS1009 in combination with azacitidine and venetoclax for relapsed\/refractory AML with MDS-related changes (AML-MR) after prior venetoclax treatment","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/ajh.27647","article-title":"Allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia with myelodysplasia-related genetic features: Relevance of the genetic underlying category. A retrospective analysis on behalf of the acute leukemic woking party of the EBMT","volume":"100","author":"Esteve","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_56","unstructured":"Ngo, T., Raj, K., Zhang, J., O\u2019Nions, J., Gupta, R., Pavne, E., Sellar, R., Kottaridis, P., Burt, R., and Mansour, M. (2026, January 11\u201314). Real world comparison of intensive chemotherapy compared to non-intensive treatment of myelodysplasia-related acute myeloid leukemia (AML-MR). Proceedings of the EHA Meeting, Stockholm, Sweden."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/5958\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:53:16Z","timestamp":1785412396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/5958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":56,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15155958"],"URL":"https:\/\/doi.org\/10.3390\/jcm15155958","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}